Understanding and Preventing Meningococcal Meningitis

banner-brain

TAKE ACTION TODAY TO PROTECT YOUR BELOVED CHILD AND FAMILY!

24-48 hours

can be critical to your child’s and beloved ones (1)

Learn about prevention

Recognize warning signs

alarming-statistics

Style
number-cards

Alarming Statistics

Robot

Mortality

rate

50%

Up to

if untreated. (1)

Long-term

Consequences

1 in 5

Survivors

may suffer from hearing loss, neurological damage, or intellectual disability. (1)

Global burden

Estimated at least

1.2

Million

Cases and ~ 135,000 deaths annually due to IMD. (3)

Critical time

window

24-48

Hours

Disease can become severe within. (1)

medical-perspective

Style
medical-perspective

Medical Perspective

Brain

Meningitis

is the inflammation of the membranes surrounding the brain and spinal cord, caused by bacteria, viruses, or fungi. (4)

Virus

Meningococcal meningitis

is caused by Neisseria meningitidis. Nearly all invasive cases are due to six serogroups: A, B, C, W, X, and Y. (3)

Wanning
It is one of the leading causes of death and neurological disability in children and adolescents globally. (7)

* Image for illustrative purposes only

disease-burden

Style
Disease-burden

Disease burden

disease-burden

Disease Burden

  • 50%
  • of patients die if not treated promptly. (1)
  • 1 in 5
  • survivors experience permanent sequelae. (1)
  • Young children
  • are particularly vulnerable to long-term physical and cognitive developmental impacts. (7)

Consequences of Meningococcal Meningitis (5)

Skin scarring

Hearing loss

Vision impairment

Motor impairment

Limb amputation

Intellectual disability

Epilepsy

high-risk

Style
High-risk-group

High-Risk Groups (6)

Who needs protection?

elderly

Older adults

(65+)

  • Mortality rate can reach
  • 20%
  • in older adults even with modern antibiotics.

adult

Infants &

young children

<2 years

  • 146.321
  • deaths in children
  • under 5 due to
  • meningitis (2016 data). (7)
  • Highest risk
  • of neurological complications under 1 year. (7)

child

Adolescents

(16–23 years)

  • 24%
  • of 19-year-olds
  • may carry the bacteria asymptomatically. (9)
  • 50%
  • of cases in individuals aged 12+
  • are caused by serogroups C, Y, W. (10)
  • This is the second highest risk group (8)
  • due to living in communal environments (schools, dormitories, military).

symptoms

Style
symptoms

Symptoms and Disease Progression (12)

24 hours

2 hours

Rapid progression – Early recognition is key!

0-4 hours

0-4 hours

0–4 hours

High fever, nausea, vomiting

5-8 hours

5-8 hours

5–8 hours

Shortness of breath, cold extremities, pale skin

9-12 hours

9-12 hours

9–12 hours

Body aches, fatigue

13-16 hours

13-16 hours

13–16 hours

Stiff neck, sensitivity to light

16+ hours

16+ hours

After 16 hours

Confusion, delirium, seizures, unconsciousness

WARNING

Early recognition of sepsis symptoms can improve detection by frontline physicians and reduce time to hospitalization. (12)

transmission

Style
transmission,float-boxes-container

Transmission

1 in 10 people may carry the bacteria

without symptoms (13)

Spread via respiratory and throat secretions (e.g., saliva)

sneezing or coughing (13, 15)

Sharing items

Cups, toothbrushes

food, children's toys (14)

Close or prolonged contact

Kissing, living in the same household (13)

prevention

Style
prevention,float-boxes-container

Prevention Measures

prevetion

Consult your doctor for advice

on preventive measures, including protection against the 5 most common serogroups (A, C, W, Y, B).

Early recognition: Monitor symptoms (16).

Early detection of sepsis symptoms can improve diagnosis and reduce hospitalization time (12)

Take action now!

Don't hesitate, protect your baby and loved ones before it's too late!

robot

meningococcal

Style
meningococcal-container

Meningococcal

Meningococcal

MENINGOCOCCAL MENINGITIS

IS UNPREDICTABLE

PROTECT YOUR LOVED ONES

BY CONTACTING YOUR DOCTOR FOR CONSULTATION TODAY!

Style
footer-references

REFERENCES

(1) World Health Organization. (n.d.). Meningococcal Meningitis – WHO Regional Office for Africa. Retrieved July 7, 2025, from https://www.afro.who.int/health-topics/meningococcal-meningitis

(2) Centers for Disease Control and Prevention. (2024). CDC - Meningococcal Disease. In: Epidemiology and Prevention of Vaccine-Preventable Diseases (14th ed., Chapter 14). Retrieved July 7, 2025, from https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-14-meningococcal-disease.html

(3) Jafri, R. Z., Ali, A., Messonnier, N. E., et al. (2013). Global epidemiology of invasive meningococcal disease. Population Health Metrics, 11(1), 17. https://doi.org/10.1186/1478-7954-11-17

(4) World Health Organization. (n.d.). Meningitis. Retrieved July 7, 2025, from https://www.who.int/news-room/fact-sheets/detail/meningitis

(5) Ladhani, S. N., et al. (2020). Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. The Lancet Child & Adolescent Health, 4(4), 255–266. https://doi.org/10.1016/S2352-4642(20)30004-5

(6) Centers for Disease Control and Prevention. (2024). Meningococcal Disease – Infection Control in Healthcare Personnel. Retrieved July 7, 2025, from https://www.cdc.gov/infection-control/hcp/healthcare-personnel-epidemiology-control/meningococcal-disease.html

(7) GBD 2016 Meningitis Collaborators. (2018). Global, regional, and national burden of meningitis, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 17(12), 1061–1082. https://doi.org/10.1016/S1474-4422(18)30387-9

(8) Centers for Disease Control and Prevention. (2024). Risk Factors for Meningococcal Disease. Retrieved July 7, 2025, from https://www.cdc.gov/meningococcal/risk-factors/index.html

(9) Christensen, H., May, M., Bowen, L., Hickman, M., & Trotter, C. L. (2010). Meningococcal carriage by age: a systematic review and meta-analysis. The Lancet Infectious Diseases, 10(12), 853–861. https://doi.org/10.1016/S1473-3099(10)70251-6

(10) Centers for Disease Control and Prevention. (2025, May 9). Meningococcal Disease Surveillance and Trends. Retrieved July 7, 2025, from https://www.cdc.gov/meningococcal/php/surveillance/

(11) Choi, C. (2001). Bacterial Meningitis in Aging Adults. Clinical Infectious Diseases, 33(8), 1380–1385. https://doi.org/10.1086/323126

(12) Thompson, M. J., Ninis, N., Perera, R., et al. (2006). Clinical recognition of meningococcal disease in children and adolescents. The Lancet, 367(9508), 397–403. https://doi.org/10.1016/S0140-6736(06)67932-4

(13) Centers for Disease Control and Prevention. (2024). About Meningococcal Disease. Retrieved July 7, 2025, from https://www.cdc.gov/meningococcal/about/index.html

(14) Canadian Paediatric Society. (2020). Meningococcal disease – Caring for Kids. Retrieved July 7, 2025, from https://caringforkids.cps.ca/handouts/meningococcal_disease

(15) World Health Organization. (n.d.). Meningococcal Meningitis – WHO Regional Office for Africa. Retrieved July 7, 2025, from https://www.afro.who.int/health-topics/meningococcal-meningitis

(16) World Health Organization. (2021). Preventing and controlling meningitis outbreaks. Retrieved July 7, 2025, from https://www.who.int/publications/i/item/9789240026461

Style
Footer-references
PP-NIM-VNM-0095